ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
36 hedge funds and large institutions have $52.7M invested in ESSA Pharma in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.
163% more call options, than puts
Call options by funds: $1.57M | Put options by funds: $597K
5% more capital invested
Capital invested by funds: $50.1M → $52.7M (+$2.59M)
0% more funds holding
Funds holding: 36 → 36 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1.6% less ownership
Funds ownership: 71.37% → 69.77% (-1.6%)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$337K |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$287K |
| 3 |
DAM
DLD Asset Management
New York
|
+$222K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$106K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$84.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Deuterium Capital Management
Clearwater,
Florida
|
-$174K |
| 2 |
Morgan Stanley
New York
|
-$152K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$119K |
| 4 |
Two Sigma Investments
New York
|
-$95.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$47.4K |
EPIX Hedge Fund Activity: Q2 2025 in Review
36 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2025, worth a combined $52.7M — up 5.2% from $50.1M a quarter earlier.
Fund positioning in EPIX was balanced in Q2 2025: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 9 trimmed.
The largest buyer was LMR Partners, opening a new position worth an estimated $337K. The largest seller was Deuterium Capital Management, exiting entirely with an estimated $174K sold.
- 36 institutional investors held ESSA Pharma (EPIX) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $52.7M of ESSA Pharma stock for Q2 2025, up 5.2% quarter-over-quarter.
- 4 funds opened new ESSA Pharma positions in Q2 2025 and 4 closed out, a net change of 0 holders.
- The largest ESSA Pharma buyer in Q2 2025 was LMR Partners, an estimated $337K added.
- The largest ESSA Pharma seller in Q2 2025 was Deuterium Capital Management, an estimated $174K sold.
Based on aggregated 13F filings for Q2 2025.